VarmX key facts
- Manufacturer of therapeutic drugs designed to restore blood clotting in patients experiencing bleeding events.
- VarmX’s last known valuation is $505.0M (Sep 2025).
- It has raised $102.5M; the latest was Merger/Acquisition ($505.0M) in Sep 2025.
- Notable investors include EQT Life Sciences, InnovationQuarter, MaasInvest, BioGeneration Ventures, CSL — 13 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
Who backs VarmX
13+- ·The complete investor list: 13 names
- ·Watch VarmX: the Monday email on marks, rounds and moves
VarmX funding rounds
No funding rounds for VarmX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
VarmX valuation
VarmX's last known valuation is $505 million, from Sep 2025. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
VarmX investors
13 investors are on record for VarmX, including EQT Life Sciences, InnovationQuarter, MaasInvest and BioGeneration Ventures.
About VarmX
Manufacturer of therapeutic drugs designed to restore blood clotting in patients experiencing bleeding events. The company offers drugs based on modified recombinant human coagulation factors effective in the presence of direct factor anticoagulants, enabling physicians and healthcare providers to manage urgent bleeding and surgical care safely.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2016
- Employees
- 25
- Website
- varmx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
VarmX’s last known valuation, Sep 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.